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Cardiovascular events (CVEs) are the leading cause of death
in chronic hemodialysis patients. Results of trials in non-end-
stage renal disease (ESRD) patients cannot be extrapolated
to patients with ESRD. It is critical to test cardiovascular
therapies in these high-risk patients who are usually
excluded from major cardiovascular trials. The study
objective was to evaluate the effect of fosinopril on CVEs in
patients with ESRD. Eligible patients were randomized to
fosinopril 5 mg titrated to 20 mg daily (n¼ 196) or placebo
(n¼ 201) plus conventional therapy for 24 months. The
primary end point was combined fatal and nonfatal first
major CVEs (cardiovascular death, resuscitated death,
nonfatal stroke, heart failure, myocardial infarction, or
revascularization). No significant benefit for fosinopril was
observed in the intent to treat analysis (n¼ 397) after
adjusting for independent predictors of CVEs (RR¼ 0.93, 95%
confidence interval (CI) 0.68–1.26, P¼ 0.35). The per protocol
secondary supportive analysis (n¼ 380) found a trend
towards benefit for fosinopril (adjusted RR¼ 0.79 (95% CI
0.59–1.1, P¼ 0.099)). In the patients who were hypertensive
at baseline, systolic and diastolic blood pressures were
significantly decreased in the fosinopril as compared to the
placebo group. After adjustment for risk factors, trends were
observed suggesting fosinopril may be associated with
a lower risk of CVEs. These trends may have become
statistically significant had the sample size been larger,
and these findings warrant further study.
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End-stage renal disease (ESRD) is increasing in incidence
and prevalence around the world. The incidence of ESRD
in Europe is reported to range from 92 to 174 per million
population among various countries.1,2 The prevalence in
1999 was 700 per million population.2 It is estimated that the
rate of dialysis is increasing 3–4.3% per year in Europe.3 Of
the European countries that participated in the United States
Renal Data System data survey, Germany reported the highest
incidence of ESRD, with 174 cases per million population in
2002.4
Cardiovascular disease is the primary cause of morbidity
and mortality in the ESRD population. It is present in as
many as 50–60% of ESRD patients.4 One-year mortality is
approximately 20% among hemodialysis patients, and
cardiovascular disease accounts for 45% of this mortality.4
ESRD is associated with a 2- to 10-fold increased risk of
cardiovascular events (CVEs) as compared to patients with
normal renal function.5–8
Despite the significant degree of morbidity and mortality,
limited therapeutic options are available to prevent progres-
sion of cardiovascular disease in this growing patient
population. The majority of cardiovascular primary and
secondary prevention clinical trials have excluded patients
with advanced renal insufficiency. Therefore, it is unknown if
the results of clinical trials establishing the efficacy of
treatment strategies in the management of cardiovascular
disease apply to the ESRD population. The German Diabetes
and Dialysis study recently showed that lipid-lowering
therapy with atorvastatin did not reduce the risk of
cardiovascular mortality or morbidity in a hemodialysis
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population.9 These results emphasize the need to study
therapeutic agents in the ESRD population, as these patients
may respond differently to therapies with proven benefits in
non-ESRD patients. The Fosinopril in Dialysis (FOSIDIAL)
study was undertaken to evaluate the safety and efficacy of
long-term angiotensin-converting enzyme (ACE) inhibition
with fosinopril (Fozitecs Merck Lipha, Lyon, France) on
cardiovascular clinical outcomes in hemodialysis patients
with left ventricular hypertrophy.
RESULTS
A total of 417 patients were recruited for the study in 47
centers. Of these, 397 patients were randomized into the
study, 201 to placebo and 196 to fosinopril, and they
constitute the intention to treat sample. Fifteen patients
(eight placebo and seven fosinopril) withdrew from the study
early because of renal transplantation. Protocol violations
occurred in two patients (both placebo); thus, the per
protocol sample consists of 380 patients. Baseline character-
istics between groups were similar, but some differed
significantly. Patients in the fosinopril group had a higher
baseline risk than patients in the placebo group as reflected
by a significantly higher baseline left ventricular (LV)
mass index and a trend towards higher rates of diabetes,
hyperlipidemia, coronary artery disease, peripheral artery
disease, stroke, and prior transplantation. Other significant
differences were present including baseline body mass index,
duration of renal replacement therapy, and use of oral
antidiabetic agents (Table 1). The mean dose of study drug
achieved was 13.275.5 mg/day in the fosinopril group.
The primary end point event rate was 32.7% over the
2-year follow-up in the whole population. The adjudicated
composite annual CVE rate and the individual components
are reported in Table 2.
By using Cox proportional hazards survival regression on
time to first CVE, a treatment-independent prognostic model
was developed in a first step and found that LV mass, age,
diabetes, coronary artery disease, stroke, and peripheral
artery disease were significant and independent predictors of
CVEs. The other available predictors as well as interactions
were not significant. In the second step, the treatment
variable was entered into this model. No significant adjusted
effect of fosinopril was detected (RR¼ 0.929, 95% confidence
interval (CI) 0.68–1.26, P¼ 0.35) (Table 3). The per protocol
data were also evaluated as a secondary supportive analysis
(n¼ 380). A nonsignificant trend towards treatment benefit
for fosinopril was observed (adjusted RR¼ 0.795 (95% CI
0.59–1.1, P¼ 0.099)) (Table 4).
The mean systolic blood pressure (SBP) at 24 months in
the 294 patients with blood pressure data at this time point
was 139722 mm Hg in the fosinopril group and
143722 mm Hg in the placebo group (P¼ 0.07). Diastolic
blood pressure (DBP) was 76711 and 74711 mm Hg in the
fosinopril and placebo groups, respectively (P¼ 0.08). A
summary measure of blood pressure was calculated by
averaging the post-baseline blood pressure measurements
from 17 visits. A two-way analysis of variance indicated a
significant interaction (P¼ 0.001) between treatment and
patients who were normotensive (SBPo140 and DBPo90)
and hypertensive at baseline; thus, the treatment effect was
analyzed separately within these patient classifications.
No difference was observed between treatment groups for
the change in SBP or DBP from baseline to the summary
measure for patients who were normotensive at baseline
(change in SBP P¼ 0.91; change in DBP P¼ 0.981). A greater
reduction in both SBP and DBP was observed for fosinopril-
treated patients who were hypertensive at baseline (change
in SBP P¼ 0.002; change in DBP P¼ 0.01) (Table 5).
The proportion of patients responding to treatment was
defined as those with mean SBPo140 mm Hg and mean
DBPo90 mm Hg, with no hypotensive adverse events.
Fosinopril was associated with a greater relative response to
treatment compared to placebo in the subset of patients who
were hypertensive at baseline (RR 1.85, 95% CI 1.18–2.89,
P¼ 0.008) (Table 5) (Figure 1).
Table 1 | Baseline characteristics
Placebo
(N=201)
Fosinopril
(N=196) P-value
Age (years) 67 (8) 67 (8) 0.72
Pre-dialysis BMI 27 (6) 26 (5) 0.02
Baseline SBP (mm Hg) 145 (20) 146 (19) 0.48
Baseline DBP (mm Hg) 77 (11) 77 (11) 0.74
2-week SBP (mm Hg) 148 (21) 147 (22) 0.63
2-week DBP (mm Hg) 78 (12) 77 (12) 0.57
Pulse pressure (mm Hg) 70 (17) 70 (17) 0.79
LV mass indexa 169 (52) 179 (54) 0.001
Female 99 (49) 90 (46) 0.51
Coronary artery disease history 21 (10) 32 (16) 0.05
Peripheral artery disease history 28 (14) 35 (18) 0.26
Stroke history 11 (6) 18 (9) 0.1
Smoking 22 (11) 24 (12) 0.68
Diabetes 56 (28) 68 (35) 0.12
Dyslipidemia 73 (36) 83 (42) 0.21
Residual diuresis (ml/day) 308 (412) 232 (329) 0.07
Duration of renal replacement
therapy (years)
4.4 (4.7) 5.3 (6) 0.04
Duration of dialysis (years) 3.8 (4) 4.4 (5) 0.11
Kt/V 1.3 (0.3) 1.4 (0.5) 0.08
Interdialytic weight change (kg) 2.4 (1) 2.3 (1) 0.22
Study drug treatment duration (days) 541 (269) 537 (271) 0.87
HDL (mmol/l)b 1.1 (0.3) 1.1 (0.3) 0.71
LDL (mmol/l)b 3.1 (1) 3.1 (1) 0.87
C-reactive protein (mg/l) 13.1 (19.7) 12.5 (17.8) 0.76
Erythropoeitin 156 (78) 157 (80) 0.56
Oral anti-diabetic therapy 3 (2) 12 (6) o0.001
Insulin 41 (20) 40 (20) 0.99
Lipid-lowering therapy 49 (24) 51 (26) 0.7
Antihypertensive therapy 103 (51) 107 (55) 0.51
Prior transplantation 11 (6) 18 (9) 0.1
BMI, body mass index; DBP, diastolic blood pressure; HDL, high-density lipoprotein;
Kt/V, volume of fluid cleared of urea during a single treatment; LDL, low-density
lipoprotein; LV, left ventricular; SBP, systolic blood pressure.
Continuous variables are reported as mean (s.d.), dichotomous variables are
reported as N (%).
aTest performed on log-transformed data.
bTo convert HDL or LDL from mmol/l (SI units) to mg/dl, divide by 0.0259.
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Safety
After the test dose, six patients experienced symptomatic
hypotension and were not randomized in the study. Patients
randomized to fosinopril had a higher rate of gastrointestinal
side effects (17.5 versus 9.5%). The rates of other adverse
events were similar between treatment groups. Baseline
potassium was 4.970.8 mEq/l in both groups. No significant
differences in potassium were observed at any time point
during the study. The mean difference between baseline
and last visit serum potassium values was 0.171.0
and 0.17.9 mEq/l in the fosinopril and placebo groups,
respectively.
DISCUSSION
Patients randomized to fosinopril appeared to have a lower
risk of CVE after adjusting for known risk factors. The
unadjusted data are of limited value because of imbalances in
important prognostic factors between groups. Thus, the best
estimate of fosinopril’s effect is provided by the adjusted data.
However, definitive conclusions cannot be drawn from
this observation. A larger study population is needed to
Table 2 | Components of the composite end point (count and
1-year event rate)
All
Primary end point 130 (16.1%)
All cause death 103 (12.3%)
CV death 63 (7.1%)
Non-CV death 40 (4.9%)
Myocardial infarction 16 (2.0%)
Unstable angina 14 (1.7%)
Coronary revascularization 33 (4.2%)
All cause hospitalization 242 (30.2%)
Heart failure hospitalization 54 (6.5%)
Resuscitated cardiac arrest 5 (0.5%)
Stroke 15 (1.8%)
Mesenteric infarction 5 (0.7%)
CV, cardiovascular.
Table 3 | Cox proportional hazards model: intent to treat
sample
Variable RR 95% CI P-value
Age (years) 1.02 1.00–1.05 0.052
Diabetes 1.34 0.91–1.97 0.136
Coronary artery disease 2.14 1.35–3.39 0.001
Stroke 1.64 0.94–2.87 0.08
Peripheral artery disease 2.00 1.29–3.11 0.002
LV massa 24.05 6.21–93.11 0.000
Fosinopril treatment 0.93 0.68–1.26 0.35
CI, confidence interval; LV, left ventricular.
aLog transformed.
Table 4 | Cox proportional hazards model: per protocol
sample
Variable RR 95% CI P-value
Diabetes 1.3 0.87–1.92 0.2
Coronary artery disease 2.44 1.53–3.89 0.000
Stroke 1.68 0.94–2.99 0.08
Peripheral artery disease 2.04 1.30–3.19 0.002
LV massa 18.52 4.62–74.36 0.000
Fosinopril treatment 0.795 0.59–1.1 0.099
CI, confidence interval; LV, left ventricular.
aLog transformed.
Table 5 | Change in SBP and DBP
Placebo Fosinopril
Difference
(95% CI)
P-value
(ANCOVA)
Normotensive patients (n=159)
Change in SBP 5.3 (14.2) 5.1 (11.9) 0.23 (4.6, 4.1) 0.91
Change in DBP 1.2 (7.4) 1.2 (7.9) 0.03 (2.3, 2.2) 0.98
Hypertensive patients (n=238)
Change in SBP 5.4 (15.4) 11.7 (13.4) 6.3 (10.3, 2.4) 0.002
Change in DBP 2.1 (9.1) 4.9 (9.7) 2.8 (5.1, 0.5) 0.01
Response proportion (o140/90 and no DBP value o50 mm Hg)
Normotensive 65% (84) 71% (75) RR 1.08 (0.87–1.33) 0.49
Hypertensive 19% (117) 35% (121) RR 1.85 (1.18–2.89) 0.008
ANCOVA, analysis of covariance; CI, confidence interval; DBP, diastolic blood pressure; SBP, systolic blood pressure.
1.0
0.9
0.8
0.7
Ev
en
t-f
re
e 
su
rv
iva
l
0 200 400 600 800
Time (days)
N =397 N =347 N =312 N =283
Placebo
Fosinopril
Figure 1 | Occurrence of primary end point by treatment group.
Cox proportional hazard survival adjusted for age and baseline
severity. ITT analysis: RR¼ 0.929, P¼ 0.35; per protocol analysis,
RR¼ 0.795, P¼ 0.09. X-axis provides time (days) and the
corresponding number of at-risk patients.
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determine if a statistically significant reduction in risk can
be detected. Because the overall event rate was lower than
anticipated, the FOSIDIAL study lacked statistical power to
definitively determine the effect of fosinopril in patients with
ESRD and left ventricular hypertrophy.
ACE inhibition is established therapy for prevention of
CVEs in patients with prior myocardial infarction (MI), or in
other high-risk patients.10 This guideline recommendation
is based on the results of multiple large clinical trials
demonstrating a reduction in clinical events for post-MI,
heart failure, and stable coronary disease patients receiving
ACE-inhibitor therapy.11–17 However, patients with ESRD on
hemodialysis were excluded from these trials. As a result, it is
not known if the results of these studies also apply to the
large population of ESRD patients at high risk of CVEs. In
the Heart Outcomes Prevention Evaluation (HOPE) and
Trandolapril in Patients with left Ventricular Dysfunction
after Myocardial Infarction (TRACE) trials, patients with
serum creatinine above 200 mmol/l (2.3 mg/dl) were ex-
cluded.15,17,18 Serum creatinine above 221 mmol/l (2.5 mg/dl)
was an exclusion for participation in the Survival and
Ventricular Enlargement study (SAVE).19 In the recent
European Trial on Reduction of Cardiac Events (EUROPA)
with Perindopril in Stable Coronary Artery Disease, patients
with serum creatinine above 150 mmol/l (1.7 mg/dl) were
excluded.14 The exclusion of patients with renal insufficiency
has also been observed in heart failure trials. In an analysis of
59 heart failure randomized controlled trials, renal insuffi-
ciency was an exclusion criterion in 11 studies (19%).20 Thus,
the degree to which patients with ESRD may benefit from
ACE inhibitor therapy cannot be determined in the absence
of a study including this group of patients. A critical need
exists to obtain these data as the prevalence of ESRD is
expected to climb.1
Several lines of evidence suggest that ESRD patients may
benefit from ACE-inhibitor therapy to a similar degree as
patients without renal failure, although no prospective,
randomized clinical trials have been carried out to confirm
or refute this hypothesis. A retrospective analysis of the
HOPE trial evaluated the relationship between renal function
and outcomes by analyzing the effect of ramipril in the subset
of patients with renal insufficiency. In this analysis, renal
insufficiency was defined as a serum creatinine4124 mmol/l
(1.4 mg/dl). A total of 980 patients met this criterion. As
expected, cardiovascular and all-cause mortality rates were
significantly higher in the patients with renal insufficiency.
The risk reduction in the primary end point for ramipril was
similar in patients with renal insufficiency (hazard ratio 0.8
(0.59–1.09)) and in those without renal insufficiency (hazard
ratio 0.79 (0.7–0.88)). The risk reduction for all-cause
mortality appeared to be higher in the renal insufficiency
group as compared to those without renal insufficiency
(hazard ratio 0.59 (0.42–0.83) versus hazard ratio 0.9
(0.79–1.03), P for heterogeneity¼ 0.0038).18 Importantly,
no difference in adverse events was observed between patients
with renal insufficiency and normal renal function. However,
this subgroup analysis was performed only in patients with
mild renal insufficiency, and the results cannot be extra-
polated to patients with ESRD on hemodialysis.
A retrospective analysis of the SAVE study also suggested
that captopril was equally efficacious in patients with and
without chronic kidney disease.19 The effect on patients with
ESRD could not be evaluated in this analysis as patients with
serum creatinine above 221 mmol/l (2.5 mg/dl) were excluded
from the SAVE trial. Patients were divided into quartiles
according to baseline estimated glomerular filtration rate
(eGFR). The baseline serum creatinine was 159.1 mmol/l
(1.8 mg/dl) and the baseline eGFR was 38 ml/min in the
lowest quartile of eGFR. Thus, these data are not reflective of
an ESRD population. The retrospective analysis showed that
captopril was associated with a greater risk reduction in total
mortality and cardiovascular morbidity/mortality in patients
with eGFRs of o60 ml/min as compared to those with eGFR
above this level. The absolute benefit of captopril was greatest
in the lowest eGFR quartiles.19
Berger et al.21 conducted a retrospective analysis of the
Cooperative Cardiovascular Project to study the patterns of
care and effectiveness of post-MI therapies in elderly patients
with ESRD. The study sample included patients 65 years
of age and older with acute MI. Patient records in the
Cooperative Cardiovascular Project database were matched
to the United States Renal Data System database to identify
those patients with ESRD. The final cohort included 146 765
patients. Of these, 145 740 did not have ESRD and 1025 were
receiving chronic hemodialysis. ACE-inhibitor use was lower
in patients receiving dialysis who were otherwise candidates
for ACE-inhibitor therapy as compared to those without
ESRD (27.6 versus. 37.2%, Po0.001). Among dialysis
patients, ACE-inhibitor use was associated with a significant
30-day mortality reduction (17.3 versus 33.4%, Po0.001).
After adjusting for baseline demographic and clinical risk
factors, the association between ACE inhibitor use and lower
mortality persisted (RR 0.58 (0.42–0.77)).21
A retrospective analysis reported by Efrati et al.22 also
suggested improved survival for hemodialysis patients treated
with ACE inhibitors. The investigators studied the effects of
ACE inhibitors on mortality in patients undergoing long-
term hemodialysis therapy. Patients receiving hemodialysis
between 1994 and 2000 were included in the study. Sixty
patients had been treated with ACE inhibitors during this
period, and 66 patients had not been prescribed ACE
inhibitors. Patients who were treated with ACE inhibitors
had a significantly lower mortality rate as compared to those
who were not treated (RR 0.48, 95% CI 0.25–0.91;
Po0.0019). Change in blood pressure was not different bet-
ween groups. These data suggest that a survival benefit may
be associated with ACE-inhibitor therapy in hemodialysis
patients.22
Similar findings have been reported by McCullough
et al.23 The investigators analyzed prospectively collected
registry data in 386 ESRD patients admitted to a coronary
care unit for heart failure or acute coronary syndromes. An
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adjusted analysis demonstrated a 37% reduction in all-cause
mortality in patients who received ACE-inhibitors versus
those who did not during a 3-year follow-up period
(P¼ 0.0145). This single-center, retrospective database ana-
lysis provides additional data suggesting that ACE inhibitors
may be associated with important clinical benefits in patients
with ESRD.
Although these retrospective analyses suggest that a
clinical benefit is present with ACE inhibitors in ESRD,
observational analyses alone are not sufficient to assess the
efficacy and safety of ACE-inhibitor use in this setting. The
recent study by Wanner et al.9 demonstrates the importance
of conducting prospective, randomized trials in this popula-
tion. Observational data have suggested that patients with
ESRD benefit from statin therapy, but this approach had
never been tested in a randomized controlled trial. The
German Diabetes and Dialysis Study randomized 1225
patients with ESRD to atorvastatin 20 mg/day or placebo.
The primary end point of the study was a composite of
cardiovascular death, fatal stroke, nonfatal MI, or nonfatal
stroke. After 3 years of follow-up, 31.9% of patients in the
atorvastatin group and 30.5% of patients in the placebo
group experienced the primary end point. No statistical
difference was detected between groups. Of concern, there
appeared to be a higher risk of fatal stroke in the atorvastatin
group as compared to the placebo group (RR 2.03, 95% CI
1.05–3.93, P¼ 0.04). The authors hypothesize that the
pathogenesis of CVEs in patients receiving hemodialysis
differs from patients without ESRD, and that statin therapy
may not influence these pathologic processes. In addition, the
authors hypothesized that once patients have progressed to
the point of ESRD, they have a lower chance of benefiting
from cardiovascular prevention strategies.
Safety is an important concern with the use of ACE
inhibitors in this patient population. Patients on hemodia-
lysis receiving either ACE inhibitors or angiotensin receptor
blockers have a significantly higher risk of developing
hyperkalemia compared with ESRD patients not receiving
these drugs, even after adjusting for other risk factors.24
Importantly, the change in serum potassium observed in
FOSIDIAL was minimal, and there was no difference in the
rate of hyperkalemia between the fosinopril and placebo
groups. Fosinopril had a favorable safety profile in this study
that may be related to the unique pharmacokinetic profile of
this agent among other ACE inhibitors. It is hepatically and
renally eliminated. In the setting of renal failure, it
accumulates to a lesser degree than lisinopril or enalapril.25–27
Important knowledge has been gained from the FOSI-
DIAL trial. First, this trial allowed for a contemporary,
accurate estimate of overall and CVE rates in patients with
ESRD in a typical European country. To adequately test the
effect of fosinopril in patients with ESRD in a randomized,
placebo-controlled trial, 476 patients per group or almost
1000 total patients would be needed for 90% power to detect
a 33% reduction in the event rate, assuming an overall
event rate of 32.7%. CVE rates in the ESRD population may
differ across geographic regions. These differences should
be considered in the design of future intervention studies.
Second, a Critical Events Committee used a rigorous
adjudication process to classify clinical events. As a result,
detailed information was collected on the type of events
occurring in this population. These data have not been
previously available, and they will guide the development of
future studies in this population. It is critical to precisely
estimate the event rate for individual components of
composite end points, because they are most likely to be
used in future trials for the sake of optimizing sample size.
After adjustment for baseline differences and other risk
factors, trends were observed suggesting fosinopril may be
associated with a lower risk of CVE. These trends may have
become statistically significant had the sample size been
adequate, and these findings warrant further study in larger
trials. The data indicate with 90% confidence that fosinopril
was associated with a modest expected CVE risk reduction of
at least 0.8–0.9. Further research in an adequately powered
study is needed based on these trends and other published
data from retrospective and observational analyses. ACE
inhibitors are currently used clinically in patients with ESRD,
and it is appropriate to study their efficacy and safety in these
patients, who are traditionally excluded from cardiovascular
clinical trials.
MATERIALS AND METHODS
The design of FOSIDIAL has been published.28 Briefly, the study was
a phase III, controlled, randomized, double-blind study of fosinopril
or placebo. Patients were eligible for enrollment if they met the
following criteria: men or postmenopausal women 50–80 years of
age; hemodialysis for at least 6 months with three sessions per week;
and left ventricular hypertrophy defined by a cardiac mass index
4130 g/m2 for men and 100 g/m2 for women within 3 months of
enrollment. The major exclusions to participation were ACE-
inhibitor use; hyperkalemia (X6 mmol/l); or hypersensitivity to
ACE inhibitors. The study was conducted at 47 centers in France,
and it was approved by the local ethics committee on human
research. All study procedures were performed in accordance with
the Declaration of Helsinki Principles. All patients provided written
informed consent.
All patients underwent a 2-week single-blind run-in period.
Patients received a test dose of fosinopril 5 mg. Blood pressure was
measured every 30 min for 4–6 h after administration of this dose.
Patients with symptomatic hypotension or SBP below 95 mm Hg
were dropped from the study. Patients were then randomized to
receive double-blind treatment with fosinopril or placebo for 24
months. Patients who tolerated the initial dose were entered into a
3- to 6-week up-titration period. The study medication dose was
increased weekly in increments of 5 mg until the target dose of
20 mg daily was achieved. Concomitant therapy was allowed during
the study period with the exception of ACE inhibitors or angiotensin
receptor blockers. The duration of follow-up was 2 years.
The primary end point was the occurrence of CVE, defined as the
composite of cardiovascular death, nonfatal MI, unstable angina,
stroke, revascularization (percutaneous coronary intervention or
coronary artery bypass grafting), hospitalization for heart failure,
and resuscitated cardiac arrest at 24 months. Secondary end points
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included change in SBP and DBP, individual components of the
composite end point, event-free survival, time to first event, all-
cause mortality, and all-cause hospitalizations. All clinical events
were adjudicated by a Critical Events committee according to pre-
established definitions. MI was defined by the presence of at least
two of the following criteria: prolonged (420 min) chest pain, new
Q wave (40.04 sþ40.2 mV) in at least two concordant electro-
cardiogram derivations, new R wave predominant in V1, or CK or
CKMB, troponin, or myoglobin greater than twice the upper limit of
the normal range. Unstable angina was defined by a prolonged
(420 min) chest pain and ST or T wave electrocardiogram ischemic
changes. Heart failure was defined by a period of 424 h
hospitalization for new onset or worsening of dyspnea with signs
and symptoms of clinical and/or radiological signs of peripheral
and/or pulmonary congestion and documented worsening of
cardiac function (increase in X-ray cardiothoracic ratio or increase
of echocardiogram LV dimension with decrease in LV shortening
fraction or increase in heart catheterization pulmonary capillary
wedge pressure or LV filling pressure). In addition or alternatively,
the dialysis strategy had to be changed for up to one consecutive
month, including increase in weekly dialysis duration 420% and/or
increase in baseline weight 41 kg, and/or switch to hemofiltration.
These changes could not be in response to an omission or reduction
in routine dialysis. Stroke was defined as focal neurological deficit
lasting 424 h with concordant documented new computed
tomography scan or magnetic resonance imaging cerebral lesion
or hemorrhage (excluding iatrogenic or traumatic causes).
Statistical methods
It was originally estimated that 198 patients per group would
provide 90% power to detect a CVE relative risk for fosinopril versus
placebo of less than 0.66 (true difference of 16%). This estimation
was based on an alpha level of 0.05, and an assumed putative
placebo event rate of 50% during a 2-year follow-up period. The
main analysis was carried out on both an intention to treat basis and
on the per protocol sample. The per protocol findings are
considered as supportive.
A blind interim analysis revealed an estimated CVE of 30%, a
value that was much lower than the anticipated rate of 50%. The
hypothesized risk reduction was unchanged, and the corresponding
true difference of 10% instead of 16% resulted in a noticeably poor
type 2 risk (b¼ 0.45). To increase the study’s power, an adjustment
model was developed to account for differences in clinically relevant
predictors. The following factors were included in the model:
previous cardiovascular history (stroke, coronary artery disease,
peripheral artery disease) and known comorbidities (age, LV mass,
diabetes). Center was used as a random variable and was considered
to account for possible extraneous variation. A two-stage analysis
was planned a priori. The first step consisted of detecting
determinant predictors using a systematic exploratory stepwise
Cox proportional hazards survival regression (including first-order
interactions) without entering the treatment effect into the model.
Predictors were retained if they were significant at a minimum level
(Po0.15). In the second step, the treatment effect was tested at a
one-sided 0.05 level, after adjusting for the retained predictors
identified in the final model found in step 1. Thus, treatment factor
and its interactions were adjusted by the retained predictors. This
procedure has been shown to be safely used in preserving global type
1 error, and it is recommended in clinical trials where the predictors
in a pathology are a priori not known.29
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